Clinical trials: First Line Treatment
Non-Squamous Non-Small Cell Neoplasm of Lung
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC
This is a randomized, multicenter, double-blind placebo-controlled phase 3 study of efficacy and safety of BCD-100 in combination with pemetrexed+cisplatin/carboplatin compared to placebo in combination with…
- Trial name
- DOMAJOR (NCT03912389)
- Testing
- BCD-100, Pemetrexed, Cisplatin (or carboplatin)
- Where
- 37 sites in Czechia, Georgia and 4 more
- Volunteers
- 292 people
- Sponsor
- Biocad
Neoplasms, Endometrial
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer
This study will evaluate the safety of dostarlimab in combination with carboplatin and paclitaxel followed by monotherapy when administered as a first-line treatment in advanced or recurrent endometrial cancer (EC).
- Trial name
- NCT07652515
- Testing
- Dostarlimab, Carboplatin, Paclitaxel
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Sepsis
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.
This study will directly compare meropenem with standard first line antibiotic therapies in subjects entering an ICU with secondary nosocomial sepsis, or who contract sepsis while resident in an ICU.
- Trial name
- NCT00318552
- Testing
- Meropenem
- Where
- 12 sites in Hungary
- Volunteers
- 160 people
- Sponsor
- Pfizer
Lung Cancer
Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)
Multinational, multi-center medical record review to describe the treatment patterns, clinical outcomes, and EGFR / T790M testing practices in EGFR-mutated advanced NSCLC patients receiving first-line EGFR TKI therapy in Europe.
- Trial name
- REFLECT (NCT04031898)
- Testing
- Non Interventional
- Where
- Bulgaria
- Volunteers
- 896 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to assess the efficacy and safety of QL1706 in combination with bevacizumab and/or chemotherapy versus sintilimab in combination with bevacizumab as first-line treatment in patients with advanced…
- Trial name
- NCT05976568
- Testing
- QL1706, Bevacizumab, Oxaliplatin injection
- Where
- 2 sites in China
- Volunteers
- 668 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Squamous Cell Carcinoma of Head and Neck
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
The primary objective of this study is to evaluate the efficacy of atezolizumab plus tiragolumab and atezolizumab plus placebo as first-line (1L) treatment in recurrent/metastatic PD-L1-positive squamous cell carcinoma of the…
- Trial name
- SKYSCRAPER-09 (NCT04665843)
- Testing
- Atezolizumab, Tiragolumab
- Where
- 47 sites in United States, Czechia and 11 more
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)
This is an observational follow-up study on the efficacy of 1st-line treatment with Herceptin (trastuzumab) in patients with metastatic breast cancer 7 years after initiation of treatment.
- Trial name
- NCT01332981
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Hoffmann-La Roche
Colorectal Neoplasms
TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread
This study will assess the safety and anticancer activity of TQB2922 injection given under the skin together with chemotherapy in adults with colorectal cancer that has spread, cannot be removed by surgery, and has no RAS or BRAF…
- Trial name
- NCT07844187
- Testing
- TQB2922 injection (subcutaneous administration), Oxaliplatin, Calcium folinate (leucovorin calcium)
- Where
- 16 sites in China
- Volunteers
- 64 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)
Evaluation of gemcitabine and cisplatin in combination with either sorafenib or placebo for the treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- NEXUS (NCT00449033)
- Testing
- Sorafenib (Nexavar, BAY43-9006), Gemcitabine, Cisplatin
- Where
- 122 sites in Austria, Belgium and 16 more
- Volunteers
- 904 people
- Sponsor
- Bayer
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β).
- Trial name
- FORTIFI-FLEX (NCT07807163)
- Testing
- Ficerafusp alfa, Pembrolizumab (KEYTRUDA®)
- Where
- 7 sites in United States
- Volunteers
- 160 people
- Sponsor
- Bicara Therapeutics
Hepatocellular Carcinoma (HCC)
A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
This is a multicenter, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the efficacy, safety, PK, and immunogenicity of HLX13 and YERVOY® in patients with unresectable hepatocellular…
- Trial name
- NCT06841185
- Testing
- HLX13, US-sourced YERVOY®, EU-sourced YERVOY®
- Volunteers
- 656 people
- Sponsor
- Shanghai Henlius Biotech
Acute Myeloid Leukemia
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
A study of siremadlin in combination with venetoclax plus azacitidine in adult participants with AML who are ineligible for chemotherapy.
- Trial name
- NCT05155709
- Testing
- siremadlin, venetoclax, azacitidine
- Where
- 10 sites in United States, Hong Kong and 5 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Breast Cancer
Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer
To evaluate Arimidex 6 month therapy as an adjuvant treatment in postmenopausal patients with advanced breast cancer in whom a partial or complete response or stabilized disease were obtained with first line chemotherapy, by…
- Trial name
- NCT00562458
- Testing
- anastrozole
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Endometrial Cancer
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Phase II study: Safety and preliminary efficacy of BAT1308 combined with platinum-containing chemotherapy;Phase III study: Confirmatory safety and efficacy study of BAT1308 combined with platinum-containing chemotherapy for…
- Trial name
- NCT06321068
- Testing
- carboplatin, Paclitaxel, Recombinant humanized anti-PD-1 monoclonal antibody injection
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Bio-Thera Solutions
Coccidioidomycosis
POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)
To evaluate the safety of posaconazole (POS) in the treatment of coccidioidomycosis. Period A consisted of 2 blinded arms, posaconazole and fluconazole.
- Trial name
- NCT00423267
- Testing
- Posaconazole, Fluconazole
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Breast Cancer
IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma
Open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting in patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of weekly paclitaxel (80…
- Trial name
- NCT00349934
- Testing
- IMP321
- Where
- 3 sites in France
- Volunteers
- 33 people
- Sponsor
- Immutep S.A.S.
Metastatic Pancreatic Cancer
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in combination with modified FOLFIRINOX (mFFX therapy), the standard of care, as first-line treatment in patients with metastatic pancreatic cancer.
- Trial name
- NCT06532344
- Testing
- ONO-7913, ONO-4538, Oxaliplatin
- Where
- 9 sites in Japan
- Volunteers
- 32 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2
4 cycles of induction treatment with nab-paclitaxel and carboplatin followed by nab-paclitaxel monotherapy for those subjects who are progression free at the end of 4 cycles.
- Trial name
- AboundPS2 (NCT02289456)
- Testing
- nab-Paclitaxel, Carboplatin
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Celgene
Neoplasms, Breast
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors overexpress the…
- Trial name
- NCT00347919
- Testing
- pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, lapatinib (GW572016) 1000 mg
- Where
- 84 sites in United States, Canada and 14 more
- Volunteers
- 189 people
- Sponsor
- GlaxoSmithKline
Invasive Aspergillosis
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal drug) when used in children who have invasive aspergillosis (IA) and other rare systemic fungal infections.
- Trial name
- NCT00836875
- Testing
- Voriconazole
- Where
- 25 sites in United States, Canada and 6 more
- Volunteers
- 31 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.